Results 91 to 100 of about 926 (182)

Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial

, 2019
Saroglitazar is a dual PPAR-α/γ agonist approved for the treatment of diabetic dyslipidemia. In addition to reduction in atherogenic lipids, it may also contribute to improvement in insulin sensitivity through PPAR-α/γ agonism, which remains unexplored ...
Kurpad, Anura V., Rastogi, Ashu, Sharma, Akhilesh, Kaur, Sandeep, Hawkins, Meredith, Bhansali, Shobhit, Jain, Nimisha, Bhansali, Anil   +7 more
core   +1 more source

Hypertriglyceridemia: A new paradigm

Journal of Diabetology, 2018
Low-density lipoprotein cholesterol (LDL-C) has been proven time and again to be independently associated with the risk of cardiovascular diseases (CVD). However, triglycerides (TG) are now also emerging as an important as well as independent risk factor
Johny J Kannampilly
doaj   +1 more source

Therapeutic outcome of saroglitazar, a peroxisome proliferator activated receptor α/γ agonist in diabetic and non-diabetic metabolic dysfunction associated steatotic liver disease

Background: Metabolic dysfunction associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease (CLD)and its consequences throughout the world, more so in developed countries.
Parveen, Shagufta, Kadla, Showkat A., Paul, Shashi, Shah, Nisar A., Bhat, Mohammad Hayat, Ali, Irfan   +5 more
core   +2 more sources

Inhibition of free radical activity by dual PPAR α and PPAR γ agonist using analytical assay methods

, 2017
Background: Overproduction of free radicals involved in the pathology of a wide variety of clinical disorders. Poor glycaemic control in diabetic people leads to free radical production responsible for diabetic related complications.
Vijaya Kumar A. E., S., Seethalakshami, Seethalakshami S., A. E., Vijaya Kumar, Vinay M., M., Vinay   +5 more
core   +2 more sources

UEG Week 2025 Poster Presentations

United European Gastroenterology Journal, Volume 13, Issue S8, Page S803-S1476, October 2025.
wiley   +1 more source

Do agonists of farnesoid X receptors (FXRs) and peroxisome proliferator-activated receptors (PPARs) have therapeutic potential in non-alcoholic fatty liver disease (NAFLD)?

, 2023
Introduktion: Icke-alkoholorsakad fettleversjukdom (NAFLD) kännetecknas av hepatisk fettinlagring i frånvaro av alkoholmissbruk. För en andel av patienterna leder sjukdomen till leverinflammation och fibros och benämns då icke-alkoholorsakad ...
Nyman, Agnes
core   +1 more source

Saroglitazar Reduced Liver Fat and Fibrosis in Metabolic Dysfunction Associated Steatotic Liver Disease: A Case Report

Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) is revised nomenclature of Non-alcoholic fatty liver disease (NAFLD) which is very commonly prevalent condition in India.
Kulkarni, Rajesh R.
core  

Contribution of highly active anti-retroviral therapy to the development of non-alcoholic fatty liver disease with concomitant cardiovascular dysfunction in an obese rat model [PDF]

, 2018
Thesis (PhD)--Stellenbosch University, 2018.Introduction: HIV/AIDS mortality is declining due to successful highly active anti-retroviral therapy (HAART).
Kamau, Festus Maina
core  

Different Coactivator Recruitment to Human PPARα/δ/γ Ligand-Binding Domains by Eight PPAR Agonists to Treat Nonalcoholic Fatty Liver Disease

Biomedicines
Three peroxisome proliferator-activated receptor subtypes, PPARα, PPAR(ß/)δ, and PPARγ, exert ligand-dependent transcriptional control in concert with retinoid X receptors (RXRs) on various gene sets harboring PPAR response elements (PPREs) in their ...
Shotaro Kamata, Akihiro Honda, Nonoka Kashiwagi, Ayumi Shimamura, Sayaka Yashiro, Yuna Komori, Aoi Hosoda, Noriyuki Akahoshi, Isao Ishii   +8 more
doaj   +1 more source

Saroglitazar's Therapeutic Use in Metabolic Syndrome and Nafld

Background: Saroglitazar is a novel anti-diabetic drug with combined PPAR-α/-γ agonistic activity. It was developed domestically by an Indian company called Zydus Cadila in 2001, and after numerous preclinical and clinical trials, it received regulatory approval from the Indian drug controller and regulatory authority called DCGI, India in June 2013 ...
openaire   +1 more source